<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2811">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04483960</url>
  </required_header>
  <id_info>
    <org_study_id>ERM 62646-A</org_study_id>
    <nct_id>NCT04483960</nct_id>
  </id_info>
  <brief_title>Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial</brief_title>
  <acronym>ASCOT ADAPT</acronym>
  <official_title>A Multi-centre Randomised Adaptive Platform Clinical Trial to Assess Clinical, Virological and Immunological Outcomes in Patients With SARS-CoV-2 Infection (COVID-19)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Melbourne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Peter Doherty Institute for Infection and Immunity</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Australasian Society for Infectious Diseases</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Middlemore Clinical Trials</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The George Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hunter Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The University of Queensland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Melbourne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      An International Multi-Centre Randomised Adaptive Platform Clinical Trial to Assess the&#xD;
      Clinical, Virological and Immunological Outcomes in Patients with SARS-CoV-2 Infection&#xD;
      (COVID-19).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ASCOT is an investigator-initiated, multi-centre, open-label, randomised controlled adaptive&#xD;
      platform trial. The study design will allow harmonisation with existing frameworks such as&#xD;
      the Sentinel Travellers Research Preparedness Platform for Emerging Infectious Diseases&#xD;
      (SETREP-ID) and the Randomised, embedded, multifactorial adaptive platform trial for&#xD;
      community acquired pneumonia (REMAP-CAP) study.&#xD;
&#xD;
      Platform trials allow multiple questions to be evaluated simultaneously and sequentially&#xD;
      within the platform, and evaluate interaction between different treatment options, to achieve&#xD;
      the goal of determining the optimal combination of treatments for the disease as rapidly as&#xD;
      possible. The overarching objective of ASCOT-ADAPT is to identify the regimen (combination of&#xD;
      interventions) associated with the highest chance of survival free of advanced respiratory&#xD;
      support or vasopressor / inotropic support at 28 days after randomisation, in adults&#xD;
      hospitalised with COVID-19 but not requiring ICU-level care at baseline.&#xD;
&#xD;
      In the initial implementation of the adaptive platform, recruiting sites have the option to&#xD;
      participate in one or more of three treatment domains. Consented participants will then be&#xD;
      able to choose whether to be enrolled into one or more available domains concurrently.&#xD;
      Participants will then be randomised to the corresponding interventions:&#xD;
&#xD;
      Intervention domain A (antiviral):&#xD;
&#xD;
      Participants will be randomised using response adaptive randomisation (RAR) on day 1 to&#xD;
      receive either i) standard of care without nafamostat; or ii) standard of care with&#xD;
      nafamostat&#xD;
&#xD;
      Intervention domain B (antibody):&#xD;
&#xD;
      Participants will be randomised using response adaptive randomisation (RAR) on day 1 to&#xD;
      receive either i) standard of care without convalescent plasma; or ii) standard of care with&#xD;
      convalescent plasma&#xD;
&#xD;
      Intervention domain C (anticoagulation):&#xD;
&#xD;
      Participants will be randomised using response adaptive randomisation (RAR) on day 1 to&#xD;
      receive either i) standard dose thromboprophylaxis; or ii) intermediate dose&#xD;
      thromboprophylaxis; or iii) standard dose thromboprophylaxis plus aspirin&#xD;
&#xD;
      Daily data will be collected for the first 28 days or until discharge, whichever is earlier.&#xD;
      There will be a core dataset collected for all patients at all sites and enhanced and&#xD;
      research data and biological samples for sites with capacity. Participants will be followed&#xD;
      up at Day 90.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 28, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>Participants enrolled into the study have the option of deciding whether to be randomised in one or more (if available) treatment domains concurrently, if they meet the eligibility criteria.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>This is an open-label study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Death from any cause or requirement of new intensive respiratory support (invasive or non-invasive ventilation) or vasopressor/inotropic support.</measure>
    <time_frame>28 days</time_frame>
    <description>This includes any participant who receives non-invasive mechanical ventilation (either CPAP or BIPAP, apart from the below considerations) any time after enrolment even if not transferred to ICU. It does NOT include the use of humidified high-flow nasal prong oxygen.&#xD;
Participants on pre-existing home BiPAP or CPAP will not be considered to have met the primary outcome unless they have either i. required invasive mechanical ventilation (i.e. intubation), or ii. graduated from CPAP only whilst asleep to BiPAP at any time, or iii. graduated from BiPAP only whilst asleep to BiPAP for &gt;12 hours/day, or iv. died by day 28</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to clinical recovery</measure>
    <time_frame>28 days</time_frame>
    <description>Defined as the first day, during the 28 days after enrolment, on which a patient satisfies categories 1, 2, or 3 on the WHO eight-point ordinal outcome scale. For the purposes of this outcome measure, it will be assumed that the participant is not hospitalised on the first day following discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WHO 8-point ordinal outcome scale</measure>
    <time_frame>28 days</time_frame>
    <description>The ordinal score is:&#xD;
Not hospitalised, no limitations on activities&#xD;
Not hospitalised, limitation on activities&#xD;
Hospitalised, not requiring supplemental oxygen and no longer requiring ongoing medical care (used if hospitalization was extended for infection control purposes)&#xD;
Hospitalised, not requiring supplemental oxygen but requiring ongoing medical care (COVID-19 related or other medical conditions)&#xD;
Hospitalised, requiring supplemental oxygen&#xD;
Hospitalised, on non-invasive ventilation or high flow oxygen devices&#xD;
Hospitalised, on invasive mechanical ventilation or ECMO&#xD;
Death.&#xD;
Admission to a Hospital in the Home unit is not counted as hospitalisation for the purposes of this ordinal scale. Patients who have been admitted to hospital and transferred to a Hospital in the Home unit will be assessed as either ordinal score 1 or 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>28 days and 90 days</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days alive and free of hospital</measure>
    <time_frame>28 days</time_frame>
    <description>Number of days&#xD;
Days spent in a Hospital in the Home unit will not be counted as days in hospital as hospital means 'acute-care hospital' for the purposes of this endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days alive and free of invasive or non-invasive ventilation</measure>
    <time_frame>28 days</time_frame>
    <description>Number of days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shortness of breath</measure>
    <time_frame>28 days and 90 days</time_frame>
    <description>Patient reported outcome.&#xD;
Dichotomous comparison of a subjective measure of shortness of breath such as: &quot;Are you currently experiencing shortness of breath that you didn't have before you got COVID, or which is worse now than before you got COVID?&quot;&#xD;
Ordinal comparison of the modified Medical Research Council (mMRC) breathlessness scale:&#xD;
Modified Medical Research Council (mMRC) Dyspnoea Scale for grading the severity of breathlessness during daily activities:&#xD;
0 - I only get breathless with strenuous exercise&#xD;
- I get short of breath when hurrying on level ground or walking up a slight hill&#xD;
- On level ground, I walk slower than people of the same age because of breathlessness, or I have to stop for breath when walking at my own pace on the level&#xD;
- I stop for breath after walking about 100 metres or after a few minutes on level ground&#xD;
- I am too breathless to leave the house or I am breathless when dressing or undressing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>28 days and 90 days</time_frame>
    <description>Measured by the EQ-5D-5L questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antiviral domain-specific outcome: Viral clearance</measure>
    <time_frame>3 and 7 days</time_frame>
    <description>Proportion of patients with negative SARS-CoV-2 RT-PCR from upper or lower respiratory tract samples, for those with results available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antiviral domain-specific outcome: Viral load</measure>
    <time_frame>3 and 7 days</time_frame>
    <description>Changes in cycle threshold value in RT-PCR for SARS-CoV-2 from baseline to day 3 and from baseline to day 7, for those with results available from the same respiratory tract sample type.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antiviral domain-specific outcome: Safety (Liver enzymes)</measure>
    <time_frame>Up to day 28 or day of discharge from hospital, whichever is earlier</time_frame>
    <description>o Elevation of Alanine Transaminase (ALT) or Aspartate Transaminase (AST) to &gt;5x upper limit of normal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antiviral domain-specific outcome: Safety (potassium)</measure>
    <time_frame>Up to day 28 or day of discharge from hospital, whichever is earlier</time_frame>
    <description>o Elevation of serum potassium to &gt;5.5 mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antiviral domain-specific outcome: Safety (sodium)</measure>
    <time_frame>Up to day 28 or day of discharge from hospital, whichever is earlier</time_frame>
    <description>o Decrease of serum sodium to &lt;125 mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antiviral domain-specific outcome: Safety (bleeding)</measure>
    <time_frame>Up to day 28 or day of discharge from hospital, whichever is earlier</time_frame>
    <description>o Major bleeding as defined by the International Society on Thrombosis and Haemostasis (ISTH).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antiviral domain-specific outcome: Safety (thrombophlebitis)</measure>
    <time_frame>Up to day 28 or day of discharge from hospital, whichever is earlier</time_frame>
    <description>o Thrombophlebitis/vasculitis at IV line site</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antiviral domain-specific outcome: serious adverse reactions</measure>
    <time_frame>28 days</time_frame>
    <description>Any safety event that, in the judgment of the investigator, is both serious and either possibly, probably or definitely related to the study intervention(s).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody domain-specific outcome: Serious treatment-related adverse events</measure>
    <time_frame>Within 24 hours of treatment</time_frame>
    <description>Including:&#xD;
Serious allergic reaction or anaphylaxis&#xD;
Transfusion-related acute lung injury (TRALI)&#xD;
Transfusion-associated circulatory overload (TACO)&#xD;
Acute haemolytic transfusion reaction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody domain-specific outcome: Haemolysis</measure>
    <time_frame>Within 72 hours of last transfusion</time_frame>
    <description>Yes/No</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody domain-specific outcome: Confirmed arterial thrombosis</measure>
    <time_frame>28 days</time_frame>
    <description>Yes/no - acute myocardial infarction, ischemic cerebrovascular event, other</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody domain-specific outcome: Confirmed venous thrombosis</measure>
    <time_frame>28 days</time_frame>
    <description>Yes/No - deep vein thrombosis, pulmonary embolus, other</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anticoagulation domain-specific outcome: Confirmed deep venous thrombosis</measure>
    <time_frame>28 days</time_frame>
    <description>Yes/No</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anticoagulation domain-specific outcome: Confirmed pulmonary embolus</measure>
    <time_frame>28 days</time_frame>
    <description>Yes/No</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anticoagulation domain-specific outcome: Confirmed acute myocardial infarction</measure>
    <time_frame>28 days</time_frame>
    <description>Yes/No</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anticoagulation domain-specific outcome: Confirmed ischemic cerebrovascular event</measure>
    <time_frame>28 days</time_frame>
    <description>Yes/No</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anticoagulation domain-specific outcome: Major bleeding</measure>
    <time_frame>28 days</time_frame>
    <description>Yes/No - As defined by International Society on Thrombosis and Haemostasis (ISTH). Site of bleeding and which of the ISTH criteria are met will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anticoagulation domain-specific outcome: Clinically relevant non-major bleeding</measure>
    <time_frame>28 days</time_frame>
    <description>Yes/No - As defined by International Society on Thrombosis and Haemostasis (ISTH).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anticoagulation domain-specific outcome: Heparin-induced thrombocytopenia (HIT)</measure>
    <time_frame>28 days</time_frame>
    <description>Yes/No - During index hospitalisation</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">2400</enrollment>
  <condition>SARS-CoV-2 Infection (COVID-19)</condition>
  <arm_group>
    <arm_group_label>Antiviral - Standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of care without nafamostat mesilate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antiviral - nafamostat mesilate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nafamostat continuous IV infusion for 7 days or until day of hospital discharge at a dose of 0.2mg/kg/hour. No adjustment in dose is needed for renal impairment, including for renal dialysis. The daily dose of nafamostat should be administered in 500 mL (rate of infusion 20.8 mL/hour) of normal saline. Normal saline is recommended (due to the tendency for patients with COVID-19 towards hyponatraemia) but not mandated, and 5% dextrose would be acceptable if felt clinically appropriate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antibody - Standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No convalescent plasma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antibody - convalescent plasma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Convalescent plasma (one unit) on day 1 and day 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anticoagulation - standard dose thromboprophylaxis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be administered a standard thromboprophylactic dose of low molecular weight heparin, choice of agent according to availability and local practice at the participating site.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anticoagulation - intermediate dose thromboprophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be administered an intermediate dose of low molecular weight heparin, choice of agent according to availability and local practice at the participating site. The maximum dose of enoxaparin will be 120 mg/d, tinzaparin 125 IU/kg/day (not available within Australia), and Dalteparin 15,000 IU/d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anticoagulation - standard dose thromboprophylaxis plus aspirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be administered a standard thromboprophylactic dose of low molecular weight heparin, choice of agent according to availability and local practice at the participating site. In addition, patients will receive 100mg aspirin daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nafamostat Mesilate</intervention_name>
    <description>Nafamostat continuous IV infusion for 7 days or until day of hospital discharge at a dose of 0.2mg/kg/hour. No adjustment in dose is needed for renal impairment, including for renal dialysis. The daily dose of nafamostat should be administered in 500 mL (rate of infusion 20.8 mL/hour) of normal saline. Normal saline is recommended (due to the tendency for patients with COVID-19 towards hyponatraemia) but not mandated, and 5% dextrose would be acceptable if felt clinically appropriate.</description>
    <arm_group_label>Antiviral - nafamostat mesilate</arm_group_label>
    <other_name>Nafabelltan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Convalescent plasma</intervention_name>
    <description>Convalescent plasma (one unit) on day 1 and day 2</description>
    <arm_group_label>Antibody - convalescent plasma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <description>Patients will be administered either a standard dose or an intermediate dose of low molecular weight heparin (depending on assigned arm), choice of agent according to availability and local practice at the participating site. The maximum dose of enoxaparin will be 120 mg/d, tinzaparin 125 IU/kg/day (not available within Australia), and Dalteparin 15,000 IU/d.</description>
    <arm_group_label>Anticoagulation - intermediate dose thromboprophylaxis</arm_group_label>
    <arm_group_label>Anticoagulation - standard dose thromboprophylaxis</arm_group_label>
    <arm_group_label>Anticoagulation - standard dose thromboprophylaxis plus aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dalteparin</intervention_name>
    <description>Patients will be administered either a standard dose or an intermediate dose of low molecular weight heparin (depending on assigned arm), choice of agent according to availability and local practice at the participating site. The maximum dose of enoxaparin will be 120 mg/d, tinzaparin 125 IU/kg/day (not available within Australia), and Dalteparin 15,000 IU/d.</description>
    <arm_group_label>Anticoagulation - intermediate dose thromboprophylaxis</arm_group_label>
    <arm_group_label>Anticoagulation - standard dose thromboprophylaxis</arm_group_label>
    <arm_group_label>Anticoagulation - standard dose thromboprophylaxis plus aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tinzaparin</intervention_name>
    <description>Patients will be administered either a standard dose or an intermediate dose of low molecular weight heparin (depending on assigned arm), choice of agent according to availability and local practice at the participating site. The maximum dose of enoxaparin will be 120 mg/d, tinzaparin 125 IU/kg/day (not available within Australia), and Dalteparin 15,000 IU/d.</description>
    <arm_group_label>Anticoagulation - intermediate dose thromboprophylaxis</arm_group_label>
    <arm_group_label>Anticoagulation - standard dose thromboprophylaxis</arm_group_label>
    <arm_group_label>Anticoagulation - standard dose thromboprophylaxis plus aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>In addition to standard dose thromboprophylaxis, patients randomised to this arm will also receive 100mg aspirin daily.</description>
    <arm_group_label>Anticoagulation - standard dose thromboprophylaxis plus aspirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Platform Inclusion Criteria:&#xD;
&#xD;
          1. Age â‰¥ 18 years&#xD;
&#xD;
          2. Admitted to an acute-care hospital&#xD;
&#xD;
          3. Confirmed SARS-CoV-2 by nucleic acid testing in the past 14 days&#xD;
&#xD;
          4. Able to be randomised within 14 days of symptom onset&#xD;
&#xD;
          5. At least one symptom or sign attributable to SARS-CoV-2 infection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        A. Overall platform exclusions:&#xD;
&#xD;
          1. Currently receiving acute intensive respiratory support (invasive or non-invasive&#xD;
             mechanical ventilation) or vasopressor/inotropic support. Note, participants already&#xD;
             on community based non-invasive ventilation (either CPAP or BiPAP) can still be&#xD;
             recruited. Humidified high flow nasal oxygen will not be considered an exclusion&#xD;
             criterion.&#xD;
&#xD;
          2. Previous participation in the trial&#xD;
&#xD;
          3. Treating team deems enrolment in the study is not in the best interests of the patient&#xD;
&#xD;
          4. Death is deemed to be imminent and inevitable within the next 24 hours&#xD;
&#xD;
          5. Either the patient or their primary treating clinician are not committed to active&#xD;
             treatment.&#xD;
&#xD;
        This criterion seeks to exclude those patients where supportive comfort measures only are&#xD;
        being provided. Patients who are planned for active ward management with a clear aim to&#xD;
        improve survival, even if intensive care unit level support is not being offered, should&#xD;
        still be included.&#xD;
&#xD;
        B. Domain A (Antiviral) intervention-level exclusions:&#xD;
&#xD;
        Criteria that exclude a patient from one or more interventions are:&#xD;
&#xD;
        Nafamostat:&#xD;
&#xD;
          -  Known current decompensated liver disease (Child-Pugh B or C)&#xD;
&#xD;
          -  The treating clinician intends to continue or commence therapeutic anticoagulation&#xD;
&#xD;
          -  A current or recurrent condition with a high risk of major bleeding (e.g. bleeding&#xD;
             disorder), or a baseline coagulation profile (within the previous 3 days) that&#xD;
             indicates a high risk of bleeding, that would be considered a contraindication to&#xD;
             receive therapeutic anticoagulation&#xD;
&#xD;
          -  Serum Potassium &gt;5.5 mmol/L (based on most recent blood test result collected as part&#xD;
             of routine care within the previous 3 days)&#xD;
&#xD;
          -  Serum Sodium &lt;120 mmol/L (based on most recent blood test result collected as part of&#xD;
             routine care within the previous 3 days)&#xD;
&#xD;
          -  Hypersensitivity to nafamostat&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Currently receiving or have received nafamostat in the past 7 days&#xD;
&#xD;
          -  Decompensated heart failure or renal dialysis and clinician believes an extra 500mL&#xD;
             fluid/day would be detrimental There are no domain-level exclusions for the antiviral&#xD;
             domain.&#xD;
&#xD;
        C. Domain B (Antibody) domain-level exclusions:&#xD;
&#xD;
        Patients will be excluded from this domain if they have any of the following:&#xD;
&#xD;
          -  Participant has already received treatment with SARS-CoV-2-specific immunoglobulin&#xD;
             therapy (convalescent plasma, hyperimmune globulin or monoclonal antibody) within 3&#xD;
             months prior to enrolment;&#xD;
&#xD;
          -  Treating team deems enrolment in antibody intervention is not in the best interests of&#xD;
             the patient.&#xD;
&#xD;
        Domain B (Antibody) intervention-level exclusions:&#xD;
&#xD;
        The following are intervention exclusions:&#xD;
&#xD;
          -  Known previous history of transfusion-related acute lung injury will exclude a patient&#xD;
             from convalescent plasma;&#xD;
&#xD;
          -  Known previous history of serious allergic reaction to blood product transfusion will&#xD;
             exclude a patient from convalescent plasma;&#xD;
&#xD;
          -  Known personal or religious objections to receiving blood products will exclude a&#xD;
             patient from receiving convalescent plasma;&#xD;
&#xD;
        D. Domain C (Anticoagulation) domain-level exclusions:&#xD;
&#xD;
        Patients will be excluded from this domain if they have any of the following:&#xD;
&#xD;
          -  Receiving dual antiplatelet therapy&#xD;
&#xD;
          -  The treating clinician intends to continue or commence therapeutic anticoagulation&#xD;
             Contraindication to receiving low molecular weight heparin or unfractionated heparin,&#xD;
             including the known or suspected history of heparin-induced thrombocytopenia or other&#xD;
             adverse reaction to prior heparin exposure such as hypersensitivity&#xD;
&#xD;
          -  Severe thrombocytopenia (platelet count less than 30 x 109/L)&#xD;
&#xD;
          -  History of intracranial haemorrhage in the previous 3 months&#xD;
&#xD;
          -  Severe renal impairment, defined as estimated glomerular filtration rate less than&#xD;
             15ml/min/1.73m2&#xD;
&#xD;
          -  A current or recurrent condition with a high risk of major bleeding (e.g. bleeding&#xD;
             disorder), or a baseline coagulation profile (within the previous 3 days) that&#xD;
             indicates a high risk of bleeding, that would be considered a contraindication to&#xD;
             receive thromboprophylaxis&#xD;
&#xD;
        Domain C (anticoagulation) intervention-level exclusion criteria:&#xD;
&#xD;
        Criteria that exclude a patient from one or more interventions are:&#xD;
&#xD;
          -  Receiving an antiplatelet agent will exclude a patient from receiving standard&#xD;
             thromboprophylaxis plus aspirin&#xD;
&#xD;
          -  Hypersensitivity to aspirin will exclude a patient from receiving standard&#xD;
             thrmoboprophylaxis plus aspirin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Tong, A/Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Melbourne Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Naomi Perry</last_name>
    <phone>+61 3 83442647</phone>
    <email>naomi.perry@unimelb.edu.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jocelyn Mora</last_name>
    <phone>+61 3 8344 0770</phone>
    <email>jocelyn.mora@unimelb.edu.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Calvary Public Bruce Hospital</name>
      <address>
        <city>Bruce</city>
        <state>Australian Capital Territory</state>
        <zip>2617</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chong-Wei Ong</last_name>
      <email>chong-wei.ong@act.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Canberra Hospital</name>
      <address>
        <city>Canberra</city>
        <state>Australian Capital Territory</state>
        <zip>2605</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sanjaya Senanayake, A/Prof</last_name>
      <email>sanjaya.senanayake@act.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Armidale Hospital</name>
      <address>
        <city>Armidale</city>
        <state>New South Wales</state>
        <zip>2350</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mark Kelly, Dr</last_name>
      <email>mark.kelly1@health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bankstown-Lidcombe Hospital</name>
      <address>
        <city>Bankstown</city>
        <state>New South Wales</state>
        <zip>2200</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ravindra Dotel</last_name>
      <email>Ravindra.Dotel@health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Blacktown Hospital</name>
      <address>
        <city>Blacktown</city>
        <state>New South Wales</state>
        <zip>2148</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marianne Ong, Dr</last_name>
      <email>Marianne.Martinello@health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Campbelltown Hospital</name>
      <address>
        <city>Campbelltown</city>
        <state>New South Wales</state>
        <zip>2560</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Belinda Cochrane</last_name>
      <email>belindacochrane@bigpond.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sebastian van Hal, A/Prof</last_name>
      <email>Sebastiaan.vanhal@health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Canterbury Hospital</name>
      <address>
        <city>Campsie</city>
        <state>New South Wales</state>
        <zip>2194</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Timothy Gray</last_name>
      <email>timothy.gray@health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Sutherland Hospital</name>
      <address>
        <city>Caringbah</city>
        <state>New South Wales</state>
        <zip>2229</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert Stevens, Dr</last_name>
      <email>Robert.Stevens@health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Coffs Harbour Health Campus</name>
      <address>
        <city>Coffs Harbour</city>
        <state>New South Wales</state>
        <zip>2450</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christiaan Mostert</last_name>
      <email>Christiaan.Mostert@health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Concord Repatriation General Hospital</name>
      <address>
        <city>Concord</city>
        <state>New South Wales</state>
        <zip>2139</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Timothy Gray, Dr</last_name>
      <email>timothy.gray@health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital Sydney</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gail Matthews</last_name>
      <email>Gmatthews@kirby.unsw.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northern Beaches Hospital</name>
      <address>
        <city>Frenchs Forest</city>
        <state>New South Wales</state>
        <zip>2086</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Mina</last_name>
      <email>michaelmina2001@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Griffith Base Hospital</name>
      <address>
        <city>Griffith</city>
        <state>New South Wales</state>
        <zip>2680</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arunavo Chatterji</last_name>
      <email>Arunavo.Chatterji@health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nepean Hospital</name>
      <address>
        <city>Kingswood</city>
        <state>New South Wales</state>
        <zip>2747</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Archana Sud, A/Prof</last_name>
      <email>Archana.Sud@health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St George Hospital</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Sullivan, Dr</last_name>
      <email>richard.sullivan@health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lismore Base Hospital</name>
      <address>
        <city>Lismore</city>
        <state>New South Wales</state>
        <zip>2480</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Coghill, Dr</last_name>
      <email>sarah.coghill@health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liverpool Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong Foo, Dr</last_name>
      <email>hong.foo@health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>John Hunter Hospital</name>
      <address>
        <city>New Lambton Heights</city>
        <state>New South Wales</state>
        <zip>2305</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joshua Davies, Dr</last_name>
      <email>Joshua.Davies@menzies.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orange Health Service</name>
      <address>
        <city>Orange</city>
        <state>New South Wales</state>
        <zip>2800</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacob Williams, Dr</last_name>
      <email>Jacob.williams@health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Port Macquarie Base Hospital</name>
      <address>
        <city>Port Macquarie</city>
        <state>New South Wales</state>
        <zip>2444</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nilar Lwin, Dr</last_name>
      <email>Nilarlwin83@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeffrey Post, A/Prof</last_name>
      <email>Jeffrey.Post@health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>St Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bernard Hudson</last_name>
      <email>bernard.hudson@health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Tweed Hospital</name>
      <address>
        <city>Tweed Heads</city>
        <state>New South Wales</state>
        <zip>2485</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alison Winning, Dr</last_name>
      <email>alison.winning@health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wagga Wagga Base Hospital</name>
      <address>
        <city>Wagga Wagga</city>
        <state>New South Wales</state>
        <zip>2650</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Timothy Gilbey</last_name>
      <email>timothy.gilbey@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Calvary Mater Newcastle</name>
      <address>
        <city>Waratah</city>
        <state>New South Wales</state>
        <zip>2298</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul Wilson, Dr</last_name>
      <email>paul.wilson@calvarymater.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew O'Sullivan, Dr</last_name>
      <email>matthew.osullivan@health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wollongong Hospital</name>
      <address>
        <city>Wollongong</city>
        <state>New South Wales</state>
        <zip>2500</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Omar Shum, Dr</last_name>
      <email>Omar.Shum@health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Darwin Hospital</name>
      <address>
        <city>Tiwi</city>
        <state>Northern Territory</state>
        <zip>0810</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Davies, Dr</last_name>
      <email>jane.davies@menzies.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunshine Coast University Hospital</name>
      <address>
        <city>Birtinya</city>
        <state>Queensland</state>
        <zip>4575</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Keat Choong, Dr</last_name>
      <email>Keat.Choong@health.qld.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Caboolture Hospital</name>
      <address>
        <city>Caboolture</city>
        <state>Queensland</state>
        <zip>4510</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nastaran Rafiei, Dr</last_name>
      <email>nastaran.rafiei@uqconnect.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cairns Hospital</name>
      <address>
        <city>Cairns</city>
        <state>Queensland</state>
        <zip>4870</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Simon Smith, Dr</last_name>
      <email>sismith17@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Prince Charles Hospital</name>
      <address>
        <city>Chermside</city>
        <state>Queensland</state>
        <zip>4032</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Burke, Dr</last_name>
      <email>Andrew.Burke@health.qld.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4120</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Stewart, Dr</last_name>
      <email>Adam.Stewart@health.qld.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mackay Base Hospital</name>
      <address>
        <city>Mackay</city>
        <state>Queensland</state>
        <zip>4740</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Janath De Silva, Dr</last_name>
      <email>Janath.Desilva@health.qld.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Logan Hospital</name>
      <address>
        <city>Meadowbrook</city>
        <state>Queensland</state>
        <zip>4131</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marjoree Sehu, Dr</last_name>
      <email>marjoree.sehu@health.qld.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Redcliffe Hospital</name>
      <address>
        <city>Redcliffe</city>
        <state>Queensland</state>
        <zip>4020</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Khin Chaw, Dr</last_name>
      <email>Khin.chaw@health.qld.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mater</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul Griffin, Dr</last_name>
      <email>Paul.griffin@mater.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gold Coast University Hospital</name>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Gerrard</last_name>
      <email>John.Gerrard@health.qld.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Townsville University Hospital</name>
      <address>
        <city>Townsville</city>
        <state>Queensland</state>
        <zip>4814</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christopher Heather, Dr</last_name>
      <email>Christopher.Heather@health.qld.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrew Henderson, Dr</last_name>
      <email>andrew.henderson@health.qld.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mark Boyd, Prof</last_name>
      <email>mark.boyd@adelaide.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Flinders Medical Centre</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nick Anagnostou, Dr</last_name>
      <email>nicholas.anagnostou@sa.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lyell McEwin Hospital</name>
      <address>
        <city>Elizabeth Vale</city>
        <state>South Australia</state>
        <zip>5112</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mark Boyd, Prof</last_name>
      <email>mark.boyd@adelaide.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Hobart Hospital</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <zip>7000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alison Ratcliff, Dr</last_name>
      <email>alison.ratcliff@ths.tas.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Launceston General Hospital</name>
      <address>
        <city>Launceston</city>
        <state>Tasmania</state>
        <zip>7250</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Flanagan, Dr</last_name>
      <email>Katie.flanagan@ths.tas.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ballarat Health Services</name>
      <address>
        <city>Ballarat Central</city>
        <state>Victoria</state>
        <zip>3350</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rob Commons, Dr</last_name>
      <email>robert.commons@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St John of God Ballarat Hospital</name>
      <address>
        <city>Ballarat</city>
        <state>Victoria</state>
        <zip>3350</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rob Commons, Dr</last_name>
      <email>robert.commons@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bendigo Health</name>
      <address>
        <city>Bendigo</city>
        <state>Victoria</state>
        <zip>3550</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Mahony, Dr</last_name>
      <email>andrew.mahony@austin.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eastern Health (Box Hill Hospital)</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lyn-Li Lim, Dr</last_name>
      <email>LynLi.Lim@easternhealth.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Monash Health</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ben Rogers, Dr</last_name>
      <email>ben.rogers@monash.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northern Health</name>
      <address>
        <city>Epping</city>
        <state>Victoria</state>
        <zip>3076</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Craig Aboltins, A/Prof</last_name>
      <email>Craig.Aboltins@nh.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital Melbourne</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Darby, Dr</last_name>
      <email>Jonathan.Darby@svha.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Frankston Hospital - Penninsula Health</name>
      <address>
        <city>Frankston</city>
        <state>Victoria</state>
        <zip>3199</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kasha Singh, Dr</last_name>
      <email>kasha.singh@unimelb.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peninsula Private Hospital</name>
      <address>
        <city>Frankston</city>
        <state>Victoria</state>
        <zip>3199</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Lister</last_name>
      <email>david.michael.lister@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Barwon Health - University Hospital Geelong</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel O'Brien, A/Prof</last_name>
      <email>daniel.o'brien@barwonhealth.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Austin Health</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Charles, Dr</last_name>
      <email>patrick.charles@austin.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cabrini Health</name>
      <address>
        <city>Malvern</city>
        <state>Victoria</state>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Sheffield, Dr</last_name>
      <email>sheffield010@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michelle Yong, Dr</last_name>
      <email>Michelle.Yong@petermac.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>James McMahon, Dr</last_name>
      <email>james.mcmahon@monash.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Sasadeusz, A/Prof</last_name>
      <email>j.sasadeusz@mh.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Epworth Richmond</name>
      <address>
        <city>Richmond</city>
        <state>Victoria</state>
        <zip>3121</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Douglas Johnson, A/Prof</last_name>
      <email>Douglas.F.Johnson@mh.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Goulburn Valley Health</name>
      <address>
        <city>Shepparton</city>
        <state>Victoria</state>
        <zip>3630</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Schulz, Dr</last_name>
      <email>Thomas.Schulz@mh.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Western Health</name>
      <address>
        <city>St Albans</city>
        <state>Victoria</state>
        <zip>3021</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Molton, Dr</last_name>
      <email>james.molton@wh.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Latrobe Regional Hospital</name>
      <address>
        <city>Traralgon</city>
        <state>Victoria</state>
        <zip>3844</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roy Chean, Dr</last_name>
      <email>rchean@lrh.com.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>West Gippsland Hospital</name>
      <address>
        <city>Warragul</city>
        <state>Victoria</state>
        <zip>3820</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alex Ctai, Dr</last_name>
      <email>alexyctai@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Albury Wodonga Health</name>
      <address>
        <city>Wodonga</city>
        <state>Victoria</state>
        <zip>3690</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Burston, Dr</last_name>
      <email>jrburston@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rockingham General Hospital</name>
      <address>
        <city>Cooloongup</city>
        <state>Western Australia</state>
        <zip>6168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Siong Hui, Dr</last_name>
      <email>siong.hui@health.wa.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Joondalup Health Campus</name>
      <address>
        <city>Joondalup</city>
        <state>Western Australia</state>
        <zip>6027</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jonathan Chambers</last_name>
      <email>Jonathan.Chambers@wdp.com.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Armadale Health Service</name>
      <address>
        <city>Mount Nasura</city>
        <state>Western Australia</state>
        <zip>6112</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David New, Dr</last_name>
      <email>David.new@health.wa.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fiona Stanley Hospita</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Edward Raby, Dr</last_name>
      <email>Edward.Raby@health.wa.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julie Hart, Dr</last_name>
      <email>Julie.hart@health.wa.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Owen Robinson, A/Prof</last_name>
      <email>Owen.Robinson@health.wa.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St John of God Subiaco Hospital</name>
      <address>
        <city>Subiaco</city>
        <state>Western Australia</state>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Astrid Arellano, Dr</last_name>
      <email>astrid.arellano71@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Knox Private Hospital</name>
      <address>
        <city>Wantirna</city>
        <zip>3152</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joseph Torresi, Dr</last_name>
      <email>josepht@unimelb.edu.au</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>July 22, 2020</study_first_submitted>
  <study_first_submitted_qc>July 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2020</study_first_posted>
  <last_update_submitted>January 20, 2021</last_update_submitted>
  <last_update_submitted_qc>January 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Melbourne</investigator_affiliation>
    <investigator_full_name>Associate Professor Steven Tong</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Nafamostat</mesh_term>
    <mesh_term>Enoxaparin</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
    <mesh_term>Tinzaparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

